Heparin Dosing for Pulmonary Embolism
For acute pulmonary embolism treatment, administer unfractionated heparin as an 80 U/kg intravenous bolus followed by 18 U/kg/hour continuous infusion, adjusting to maintain aPTT at 1.5-2.5 times control (corresponding to anti-factor Xa levels of 0.3-0.7 IU/mL).
Weight-Based Dosing Protocol
The standard weight-based regimen for IV unfractionated heparin (UFH) is 1, 2, 3:
- Initial bolus: 80 U/kg IV
- Continuous infusion: 18 U/kg/hour
- Target aPTT: 1.5-2.5 times control (approximately 45-75 seconds)
- Target anti-factor Xa: 0.3-0.7 IU/mL
This weight-based approach is superior to fixed dosing and should be preferred 2. The FDA-approved labeling confirms these dosing parameters 3.
Monitoring and Dose Adjustments
Check aPTT 4-6 hours after the initial bolus, then 6-10 hours after any dose change, and daily once therapeutic 4, 3. Use a validated nomogram for adjustments 2:
| aPTT | Dose Adjustment |
|---|---|
| <35 sec (<1.2× control) | 80 U/kg bolus; increase infusion by 4 U/kg/h |
| 35-45 sec (1.2-1.5× control) | 40 U/kg bolus; increase infusion by 2 U/kg/h |
| 46-70 sec (1.5-2.3× control) | No change |
| 71-90 sec (2.3-3× control) | Reduce infusion by 2 U/kg/h |
| >90 sec (>3× control) | Stop infusion 1 hour; reduce by 3 U/kg/h |
Alternative Parenteral Options
Low-molecular-weight heparin (LMWH) or fondaparinux are preferred over UFH for most hemodynamically stable patients (grade 2C recommendation) 1. These agents have lower bleeding risk and don't require monitoring 1, 5:
- Enoxaparin: 1 mg/kg SC every 12 hours OR 1.5 mg/kg SC once daily
- Dalteparin: 200 U/kg SC once daily
- Tinzaparin: 175 U/kg SC once daily
- <50 kg: 5 mg SC daily
- 50-100 kg: 7.5 mg SC daily
100 kg: 10 mg SC daily
When to Use UFH vs LMWH
Reserve UFH for 5:
- Hemodynamically unstable patients or high-risk PE requiring potential thrombolysis
- Severe renal impairment (CrCl <30 mL/min)
- Severe obesity
- Situations requiring rapid reversal
Use LMWH/fondaparinux for 1, 5:
- Hemodynamically stable patients
- Outpatient or early discharge candidates
- Lower bleeding risk tolerance
Critical Monitoring Requirements
Beyond aPTT monitoring, check platelet counts every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of UFH patients 1, 3. Also monitor hemoglobin, hematocrit, and stool occult blood periodically 3.
Duration and Transition
Continue heparin for at least 5 days AND until INR is therapeutic (2-3) for 2 consecutive days if transitioning to warfarin 2, 3. Start warfarin on day 1 or 2 of heparin therapy 2, 3.
Common Pitfalls
Subtherapeutic initial dosing: Failure to achieve therapeutic aPTT within 24 hours increases recurrent thromboembolism risk to 25% 7. Recent data shows 93% of patients can achieve therapeutic anticoagulation within 9 hours using weight-based protocols 8.
Renal dysfunction: Exercise caution with LMWH if CrCl <30 mL/min; use UFH or adjust LMWH doses with anti-Xa monitoring 1, 9, 5.
Accelerated clearance: Patients with PE may have accelerated heparin clearance requiring higher doses (25 U/kg/hour) compared to DVT alone 10, 11.
Anti-Xa vs aPTT: Some institutions now prefer anti-Xa monitoring (target 0.3-0.7 IU/mL) as it's more accurate and reproducible than aPTT, particularly for UFH 8.